Looks like your broker has not updated for the consolidation. Mine shows the opposite, over 9000% increase ... give them a chance and it will get sorted. If you need to sell you will have to phone them.
To reiterate, just look at the detail in the"RNS" ... this message has not been pitched at your average investor ... They are touting for a partner and have just laid out their stall ... don't panic Mr Mainwaring.
Due to the great detail contained in the report and the fact it is not a real RNS I see this as a marketing exercise set to attract pharmaceutical investment or partners. It would be interesting to find out if other forums have had the same "news".
G&M you can catch up on the presentation as it was recorded ... in all I was impressed by the openness and candor of our CEO and CFO. Danny even individually thanked those who sent in questions and did not dodge any or waffle ... Very much different from some of the presentations I have seen lately.
Soup ...Thanks for the update ... but still unsure why and how they can hide any payments from the next income statement ... Isn't it a legal requirement to declare income and expenditure in full?
The RNS stated: "Should Oxilio exercise the option, Nuformix will licence its patent estate and know-how on NXP001 in return for a significant upfront payment and additional development milestones and a royalty on net sales, capped at £2 million per annum." I don't think they will be able to hide the payments on the income statement ... why would they?